09:00

WELCOME

09:10

PLENARY SESSIONS 1

1. RIVA: Nele Kindt, Jolien Van den Dries, Katrien Janssen:
2. Science Park: Sara Landuydt: 
   Building Business on Science

10:10

BREAK

10:30

PLENARY SESSIONS 2

1. Sightera Biosciences: Hendrik Verkammen, Maxim Le Compte:
   AI powered, patient-centric solutions
2. Diana Campillo Davó:
   The search for the Holy (Grail) TCR: A crusade against cancer
3. Michaël Claessens:

PITCHES RESEARCHERS

1. Accelerate Drug Discovery with DrugVision.AI: High-Throughput Drug Screening on Patient-Derived Tumor Organoids, Christophe Deben
2. High-throughput single cell phenotypic profiling reveals selective vulnerabilities in two- and three-dimensional glioblastoma model systems, Winnok De Vos
3. Improving oral cancer surgery by intra-operative assessment of resection margins: need for objective techniques, Senada Koljenovic
4. Prediction of immune checkpoint inhibitor response in NSCLC, Inge Mertens
5. The Antwerp ATMP hub: consolidating the cell, gene and tissue engineering ecosystem, Eva Lion
6. CASUS: a fully molecular cervical cancer screening approach, based on first-void urine as an easily accessible and non-invasive source of biomarkers, Severien Van Keer
7. A novel singlet oxygen-based photoelectrochemical platform for the specific detection of nucleic acid-based cancer biomarkers, Elise Daems
8. IMPRESS: improved multiplex methylation profiling using restriction enzymes and smMIP sequencing for highly sensitive multi-cancer detection, Ken Op de Beeck

1. Novel inhibitors to inhibit the stroma-cancer cross to preventie cancer growth, Sheila Krishnadath
2. Towards complete characterisation of cancer and tumour samples with long read Nanopore sequencing, Gerben Menschaert, OHMX
3. ..
4. ..
5. ..
6. ..